David Gay focuses his practice on pharmaceutical and biotechnology intellectual property law. He has practiced in the life sciences arena for more than 20 years. He frequently counsels clients facing sophisticated issues arising from the merger of different and complex technologies.David advises established and emerging pharmaceutical and biotechnology companies on the strategic design, acquisition, and management of intellectual property portfolios, with particular attention on the integration of business objectives and competitive technologies. His experience includes evaluating patent portfolios and conducting due diligence investigations for venture capital, private, and public financing as well as for mergers and acquisitions in the pharmaceutical and biotechnology areas. A substantial portion of David's practice is devoted to patent portfolio management, U.S. and foreign patent prosecution, opposition proceedings, freedom-to-operate investigations, validity and infringement analyses, and technology licensing. In the area of strategic planning, he advises corporations on the management of portfolios in areas including metabolic engineering, protein and small molecule therapeutics, humanized antibodies, immunomodulatory agents, pharmaceutical formulations, genomics, proteomics, bioinformatics, biosensors and diagnostics, as well as in diverse areas of biochemistry, genetics, and molecular biology.